GlobeNewswire by notified

Immunicum presenterar data från det kliniska programmet DCP-001 vid European Hematology Association (EHA) 2021 Virtual Congress

Dela

Immunicum presenterar data från det kliniska programmet DCP-001 vid European Hematology Association (EHA) 2021 Virtual Congress

- Den pågående ADVANCE-II-studien, som utvärderar DCP-001 hos AML-patienter, närmar sig målet om 20 rekryterade patienter -

Immunicum AB (publ; IMMU.ST) presenterar idag kliniska data som visar DCP-001: s förmåga att inducera immunsvar mot ett brett spektrum av tumörassocierade antigener hos patienter med akut myeolisk leukemi (AML), samt prekliniska resultat av förbättrad effekt vid kombination av DCP -001 med etablerade AML-behandlingar, vid EHA 2021 Virtual Congress, som hålls 9–17 juni 2021. Sammanfattningen av dessa presentationer har kommunicerats tidigare. E-posters finns att tillgå på såväl konferensens som företagets webbplats.

"De data som presenteras vid EHA-konferensen styrker vår uppfattning om att DCP-001 potentiellt kan förbättra den dåliga behandlingsprognosen för AML-patienter genom varaktig tumörkontroll och förlängd klinisk remission", säger Jeroen Rovers, Chief Medical Officer på Immunicum. ”Vi är nära att nå målet för patientrekryteringen i vår pågående ADVANCE-II-studie som utvärderar DCP-001 hos AML-patienter med mätbar restsjukdom och ser fram emot att kunna presentera fler resultat från denna studie i slutet av året. Baserat på prekliniska data ser vi dessutom att DCP-001 har potential att förbättra behandlingsresultaten i kombination med 5-AZA och venetoclax, vilket är en etablerad behandlingsregim för patienter med AML i USA. ”

ADVANCE-II är en internationell, multicenter, öppen fas II-klinisk studie som utvärderar effekt och säkerhet i två olika doseringsregimer av Immunicums kandidat för canceråterfallsvaccin DCP-001 hos patienter med AML vilka är i fullständig remission men har en kvarvarande mätbar restsjukdom. Initiala data från studien som presenterades vid ASH 2020-mötet visade att behandling med DCP-001 är säker, tolereras väl och samtidigt kan påvisa tidiga tecken på effekt vad gäller konvertering av patienter till icke-mätbar restsjukdom, så kallad MRD-negativ status.

Bolaget följer tidigare kommunicerad tidplan och kommer att kunna presentera ytterligare data i slutet av året.

E-posters som presenteras vid EHA 2021 Virtual Congress kommer att finnas tillgängliga för registrerade deltagare via Virtual Congress-plattformen från och med 09:00 fredagen den 11 juni samt på Immunicums webbplats. 

För mer information, vänligen kontakta:

Erik Manting
Chief Executive Officer
Telefon: +31 713 322 627
E-mail: ir@immunicum.com

investerarrelationer:

Sijme Zeilemaker
Head of Investor Relations & Corporate Communication
Telefon: +46 8 732 8400
E-mail: ir@immunicum.com

pressfrågor:

Eva Mulder and Sophia Hergenhan
Trophic Communications
Telefon: +49 175 222 57 56
E-mail: immu@trophic.eu

Om Immunicum AB (publ)
Immunicum tillämpar sin framstående expertis i dendritcellsbiologi för att utveckla nya, lagringsbara (off-the-shelf), cellbaserade terapier för solida och blodburna tumörer. Med kompletterande terapeutiska angreppssätt i klinisk Fas II-utveckling baserade på intratumoral immunaktivering och canceråterfallsvaccin (relapse vaccine) är bolagets mål att förbättra överlevnad och livskvaliteten för en stor grupp cancerpatienter. Baserat i Sverige och Nederländerna, Immunicum är noterat på Nasdaq Stockholm. www.immunicum.com

Bilaga

För att se det här innehållet från www.globenewswire.com måste du ge ditt medgivande sidans topp.
För att se det här innehållet från ml-eu.globenewswire.com måste du ge ditt medgivande sidans topp.

Om

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Följ GlobeNewswire by notified

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från GlobeNewswire by notified

Baltic Horizon Fund consolidated audited results for 202329.3.2024 10:35:00 CET | Press release

Management Board of Northern Horizon Capital AS has approved the audited financial results of Baltic Horizon Fund (the Fund) for the year 2023. The financial results remained unchanged compared to the preliminary disclosure on 15 February 2024. Executing our strategy In a challenging economic landscape characterized by inflation, interest rate volatility, and recent geopolitical events, the Fund has assessed various strategic options to navigate these complexities and ensure future growth. Over the past year, our focus has been on reshaping our strategy to foster sustainable value, concentrating efforts on avenues that promise reliable and consistent growth for our investors. In light of prevailing market conditions, we firmly believe that the execution of the ‘Modern City Life’ strategy, introduced to investors in summer 2023, is paramount to their best interests. In the coming years, we expect two thirds of the Fund’s NOI to come from the centrally located ‘Modern City Life’ multi-fu

Progress on ABN AMRO share buyback programme 22 – 28 March 202429.3.2024 08:00:00 CET | Press release

Progress on ABN AMRO share buyback programme 22 – 28 March 2024 ABN AMRO reports the transaction details related to its EUR 500 million share buyback programme announced on 14 February 2024. During the week of 22 March 2024 up to and including 28 March 2024 a total of 3,000,000 shares and depositary receipts were repurchased at an average price of €15.47 for a total amount of €46,409,760.00. For detailed information on the daily repurchased shares and depositary receipts, individual share purchase transactions and weekly reports, see the ABN AMRO website at https://www.abnamro.com/en/investor-relations/information/share-buyback-programme. To date the total consideration for shares and depositary receipts repurchased amounts to €279,519,000.00 representing 55.9% of the overall share buyback programme. ABN AMRO Press Office pressrelations@nl.abnamro.com +31 20 6288900ABN AMRO Investor Relations investorrelations@nl.abnamro.com +31 20 6282282 This press release is published by ABN AMRO Ba

Public announcement in accordance with article 7:97, §4/1 of the Belgian Companies and Associations Code (“BCAC”) concerning a capital increase by contribution in kind29.3.2024 07:00:00 CET | Press release

Press release Brussels, 29 March 2024 Regulated information – Inside information Public announcement in accordance with article 7:97, §4/1 of the Belgian Companies and Associations Code (“BCAC”) concerning a capital increase by contribution in kind On 20 November 2023, Orange Belgium SA (the “Company”) received notification from Nethys SA (“Nethys”) of its wish to contribute its 25% + 1 shareholding in VOO Holding SA (“VOO”) to the capital of the Company, provided that such contribution results in Nethys holding at least 11% of the Company's share capital (after contribution), pursuant to the provisions of the shareholders' agreement entered into by and between the Company, Atlas Services Belgium SA (“ASB”) and Nethys on 2 June 2023. Nethys can be considered a “related” party to the Company within the meaning of the IAS standards, as it has significant influence over VOO within the meaning of IAS and VOO is part of the group to which the Company belongs. Date and value of the planned t

McWhorter Foundation Combats Nelson Peltz’s Outdated Ideologies and Advocates for Sustainable Inclusivity In Corporate Leadership29.3.2024 06:59:56 CET | Press release

PALM BEACH, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- C.K. McWhorter, chairman of the McWhorter Foundation, voices concerns over outdated perspectives in corporate leadership, exemplified by recent remarks from Nelson Peltz regarding Disney's film direction. After encountering instances of racism and exclusivity on Town of Palm Beach Island (known as home to Jeffrey Epstein, Nelson Peltz and others), McWhorter reflects on the disconnect between elite boardroom discussions and the realities faced by diverse communities. While briefly meeting Nelson Peltz and shaking hands after both departed separate lunches, McWhorter initially respected his insights. However, recent comments made by Peltz suggesting Disney should avoid inclusive films have raised eyebrows and prompted McWhorter to speak out. "It's concerning when influential figures like Peltz advocate against inclusivity in entertainment," McWhorter comments. "The future is in diversity and representation, especially as millennial a

Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates29.3.2024 05:24:27 CET | Press release

SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2023 and provided corporate updates. FINANCIAL HIGHLIGHTS Total revenue was approximately RMB1,503 million during 2023. The revenue from pharmaceutical products increased by approximately 58% compared to 2022. The sales revenue of TUOYI® (toripalimab) was approximately RMB919 million, representing an increase of approximately 25% compared to the previous year.Total research and development (“R&D”) expenses were approximately RMB1,937 million in 2023, representing a decrease of approximately 19% compared to 2022. The decrease in R&D expenses was mainly due to the strategic management of R&D investments in certain early-stage pipelines, while optimizing resource all

HiddenA line styled icon from Orion Icon Library.Eye